{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=102",
    "query": {
      "condition": "Cancer",
      "page": 102
    },
    "page_size": 10
  },
  "pagination": {
    "page": 102,
    "page_size": 10,
    "total_count": 50397,
    "total_pages": 5040,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=103&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=101&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T20:45:02.211Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02267603",
      "title": "Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Merkel Cell Carcinoma",
        "Stage III Merkel Cell Carcinoma AJCC v7",
        "Stage IIIA Merkel Cell Carcinoma AJCC v7",
        "Stage IIIB Merkel Cell Carcinoma AJCC v7",
        "Stage IV Merkel Cell Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2014-11-25",
      "completion_date": "2021-12-15",
      "has_results": true,
      "last_update_posted_date": "2023-07-05",
      "last_synced_at": "2026-11-07T20:45:02.211Z",
      "location_count": 13,
      "location_summary": "Palo Alto, California • San Francisco, California • New Haven, Connecticut + 9 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02267603"
    },
    {
      "nct_id": "NCT02485535",
      "title": "Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "de Novo Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Selinexor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 12,
      "start_date": "2015-09-04",
      "completion_date": "2020-07",
      "has_results": false,
      "last_update_posted_date": "2021-05-13",
      "last_synced_at": "2026-11-07T20:45:02.211Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02485535"
    },
    {
      "nct_id": "NCT05380635",
      "title": "PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous T-Cell Lymphoma/Mycosis Fungoides"
      ],
      "interventions": [
        {
          "name": "Hypericin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Soligenix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2022-05-09",
      "completion_date": "2022-08-16",
      "has_results": true,
      "last_update_posted_date": "2023-06-07",
      "last_synced_at": "2026-11-07T20:45:02.211Z",
      "location_count": 1,
      "location_summary": "Fairport, New York",
      "locations": [
        {
          "city": "Fairport",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05380635"
    },
    {
      "nct_id": "NCT06736717",
      "title": "Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Onvansertib",
          "type": "DRUG"
        },
        {
          "name": "NALIRIFOX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2025-02-17",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-11-07T20:45:02.211Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06736717"
    },
    {
      "nct_id": "NCT00030589",
      "title": "Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "bexarotene",
          "type": "DRUG"
        },
        {
          "name": "methoxsalen",
          "type": "DRUG"
        },
        {
          "name": "UV light therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Millennix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-11-07T20:45:02.211Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030589"
    },
    {
      "nct_id": "NCT02422589",
      "title": "A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "ALK-positive Advanced Tumors"
      ],
      "interventions": [
        {
          "name": "ceritinib",
          "type": "DRUG"
        },
        {
          "name": "warfarin",
          "type": "DRUG"
        },
        {
          "name": "midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2015-10-23",
      "completion_date": "2017-12-12",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-11-07T20:45:02.211Z",
      "location_count": 3,
      "location_summary": "Detroit, Michigan • San Antonio, Texas",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02422589"
    },
    {
      "nct_id": "NCT01193517",
      "title": "Azacitidine and CAPOX in Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine MTD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2010-08",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2020-04-15",
      "last_synced_at": "2026-11-07T20:45:02.211Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01193517"
    },
    {
      "nct_id": "NCT03512340",
      "title": "Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Cancers",
        "Hematologic Cancers"
      ],
      "interventions": [
        {
          "name": "SRF231",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Surface Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 148,
      "start_date": "2018-03-13",
      "completion_date": "2020-09-29",
      "has_results": false,
      "last_update_posted_date": "2020-10-20",
      "last_synced_at": "2026-11-07T20:45:02.211Z",
      "location_count": 2,
      "location_summary": "New York, New York • San Antonio, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03512340"
    },
    {
      "nct_id": "NCT03038568",
      "title": "Assessing How Normal Variations in CT Scanning Affects Its Interpretation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Colorectal Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "CT scan",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2017-01-27",
      "completion_date": "2027-01-27",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-11-07T20:45:02.211Z",
      "location_count": 2,
      "location_summary": "New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03038568"
    },
    {
      "nct_id": "NCT00461591",
      "title": "Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Apaziquone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "TURBT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 802,
      "start_date": "2007-04",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2021-03-30",
      "last_synced_at": "2026-11-07T20:45:02.211Z",
      "location_count": 74,
      "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Sun City, Arizona + 68 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00461591"
    }
  ]
}